Unjustifiable Delays In Generic Competition? Biopharma Contends There Is No Problem

 
• By Brenda Sandburg
  
Drug competition
Patent system is not being misused to unjustifiably delay drug competition, biopharma reps tell USPTO and FDA • Source: Shutterstock

More from US FDA

More from Agency Leadership